|
Home
> Company
> Chemicals
> Pharmaceutical Chemicals
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Established in1994,We produce APIs and intermediates, we are one of the biggest manufacturer of pharmaceutical products...
APIs: Mepivacaine HCL,(CAS:1722-62-9), Ropivacaine HCL,(CAS:132112-35-7), Bupivacaine HCL,(CAS:14252-80-3), Levobupivacaine HCL,(CAS:27262-48-2), Cinchocaine(Dibucaine) HCL,(CAS:61-12-1), Pramoxine HCL,(CAS:637-58-1), Prilocaine HCL,(CAS:1786-81-8), Tiotropium Bromide,(CAS:139404-48-1), Cefpirome Sulfate,(CAS:98753-19-6), Levodropropizine,(CAS:99291-24-4), Donepezil HCl,(CAS:120011-70-3), Ozagrel HCL,(CAS:78712-43-3), Foscarnet Sodium,(CAS:63585-09-1), Policresulen (Albothyl),(CAS:9011-02-3), Tiopronin,(CAS:1953-02-2), Stepronin,(CAS:72324-18-6), Propofol,(CAS:2078-54-8), Dofetilide,(CAS:115256-11-6), Adaravone,(CAS:89-25-8), Carbazochrome Sodium Sulfonate,(CAS;51460-26-5), Roxatidine Acetate HCL,(CAS:93793-83-0), Doxapram HCL,(CAS:7081-53-0), Candesartan Cilexetil,(CAS:145040-37-5), Meclofenoxate HCL,(CAS:3685-84-5), Esmolol HCL,(CAS:81161-17-3), Buflomedil HCL,(CAS:35543-24-9), Phospho Creatine Sodium,(CAS:922-32-7), INTERMEDIATES: 2,3-cyclopenteno pyridine,(CAS:533-37-9), N-(2',6'-dimethylphenl)-2-Piperidine carboxamide, 4-pyridine carboxyaldehyde,(CAS:872-85-5), 1-benzy-4-piperidine carboxyaldehyde,(CAS:22065-85-6), 5,6-dimethoxy-2-(pyridine-4-yl)methylene-indan-1-one,(CAS:Base:120014-30-4), Scopine hydrochloride,(CAS:85700-55-6), Methyl 2,2-dithienyl glycolate, Scopine-2,2-dithienyl glycolate,(CAS:136310-64-0), Cyclobutanemethanol,(CAS:4415-82-1), Methyl-T-Bromomethyl-cinnamate,(CAS:946-99-6), 1-Phenylpiperazine,(CAS:92-54-6), and others...... Please contact us if you could provide or in need of the APIs in high quality, most of our products is selled to Europe... OEM Service: No. of R&D Staff: Estimated Annual Sales (USD): US$50 Million - US$100 Million Export Percentage: Quality Control: Legal Representative/CEO: Factory Size (Sq.meters): Factory Location: Corporate Status:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||